CTOs on the Move

Shared Health Services

www.sharedhealthservices.com

 
Shared Health Services is a wound care management company that contracts with hospitals to help them open and manage successful outpatient wound care and hyperbaric centers. The mission of our Wound Care Centers is to heal chronic wounds, improve patient outcomes, help prevent limb loss and provide a profitable service for our contracted hospitals.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

K and S Associates

K and S Associates Inc. is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valley Health System

Valley Health System is a regional healthcare system that serves residents in northern New Jersey and southern New York. It comprises The Valley Hospital, Valley Home Care and Valley Medical Group. Key services include cardiology, oncology, women’s and children’s services, emergency care, orthopedics and neurosciences. Valley Health System’s Centers of Excellence offer comprehensive coordinated inpatient and outpatient programs and services to help ensure excellent clinical outcomes and quality. The Centers of Excellence include Cardiac/Heart Failure, Diabetes, Oncology, Pulmonary, Geriatrics, Total Joint and Neurovascular. Valley maintains affiliations and collaborations with Mount Sinai Health System and with Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute.

Your partner in Care

Your partner in Care is a Wakefield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advance Driving Systems Inc

Advance Driving Systems Inc is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.